Skip to main content
. 2021 Dec 29;23(1):355. doi: 10.3390/ijms23010355

Figure 6.

Figure 6

Effects of Ibrutinib post-treatment on locomotor function after SCI. (Left panel): Acute treatment with Ibrutinib improved locomotor function after SCI. The 6 mg/kg/day of seven days IP treatment with Ibrutinib resulted in improved locomotor function, measured by BBB scores, up to 28 days after contusive SCI compared to vehicle treated controls. (Right panel): Prolonged treatment with Ibrutinib for two weeks improved long-term locomotor function after SCI. The prolonged Ibrutinib (6 mg/kg/day for 14 days) resulted in long-term improved locomotor function, measured by BBB scores, up to 11 weeks after contusive SCI compared to vehicle-treated controls. Contusive SCI was produced using the Infinite Horizons impactor, 180 kdyn setting at T10. Data were presented as mean ± SEM and analyzed with repeated measures ANOVA followed by Bonferroni post-hoc analysis, * p < 0.05, ** p < 0.01, and *** p < 0.001, Ibrutinib treatment vs. vehicle treatment, n = 10 per group.